Innovative drugs to restore Neurological Function

BioAxone is a clinical-stage company developing drug candidates that have the potential to transform the lives of patients. The clinical drug candidates are in development for spinal cord injury and for cerebral cavernous malformation (CCM) - also called angioma. The company created innovative therapies based on a deep understanding of axon regeneration and neuronal signaling pathways.

Spinal cord injury is a devastating condition that generally results in sensory and motor paralysis below the level of the injury. There are more than 12,000 new injuries in the United States per year, often from motor vehicle accidents, falls, or sports accidents. There are no drugs on the market to repair neuronal damage and eliminate paralysis after spinal cord injury. BioAxone’s drug is neuroprotective, triggers regeneration of injured axons and promotes functional recovery.

Cerebral cavernous malformation is a is a blood vessel disorder where non-malignant vascular lesions form in the brain that grow, bleed and can cause strokes, seizures, and other neurological damage. In the familial form, lesions increase in number throughout life. Surgery is the only current treatment.